Source: Health Canada shortage reports · Updated Jul 15, 2026
Some Lenalidomide products are in shortage in Canada (2 of 7 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Aug 28, 2026.
A medication used to treat multiple myeloma and certain other blood cancers.
Products affected
2 / 7
In shortage since
May 1, 2026
Est. full return
Aug 28, 2026
Reports on file
9
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
TARO-LENALIDOMIDE
10MG · CAPSULE · TARO PHARMACEUTICALS INC
DIN 02507889 · since May 1, 2026, est. end Aug 28, 2026 · Disruption of the manufacture of the drug.
Active shortage
TARO-LENALIDOMIDE
15MG · CAPSULE · TARO PHARMACEUTICALS INC
DIN 02507897 · since May 1, 2026, est. end Aug 28, 2026 · Disruption of the manufacture of the drug.
Resolved
SANDOZ LENALIDOMIDE
10MG · CAPSULE · SANDOZ CANADA INCORPORATED
DIN 02518589 · ended Jun 15, 2026 · Disruption of the manufacture of the drug.
Resolved
TARO-LENALIDOMIDE
20MG · CAPSULE · TARO PHARMACEUTICALS INC
DIN 02507900 · ended Jun 25, 2025 · Disruption of the manufacture of the drug.
Resolved
TARO-LENALIDOMIDE
2.5MG · CAPSULE · TARO PHARMACEUTICALS INC
DIN 02507862 · ended Jun 20, 2025 · Disruption of the manufacture of the drug.
Resolved
TARO-LENALIDOMIDE
10MG · CAPSULE · TARO PHARMACEUTICALS INC
DIN 02507889 · ended Mar 5, 2025 · Disruption of the manufacture of the drug.
Resolved
SANDOZ LENALIDOMIDE
5MG · CAPSULE · SANDOZ CANADA INCORPORATED
DIN 02518570 · ended Oct 21, 2024 · Requirements related to complying with good manufacturing practices.
Resolved
TARO-LENALIDOMIDE
2.5MG · CAPSULE · TARO PHARMACEUTICALS INC
DIN 02507862 · ended Mar 11, 2024 · Disruption of the manufacture of the drug.
Resolved
APO-LENALIDOMIDE
20MG · CAPSULE · APOTEX INC
DIN 02507978 · ended Nov 30, 2023 · Disruption of the manufacture of the drug.
What's happening
Lenalidomide is currently affected by 2 active shortage reports filed with Health Canada by TARO PHARMACEUTICALS INC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Lenalidomide is classified under “IMMUNOSUPPRESSANTS” (ATC L04AX).
Recent changes
Jul 15, 2026
Estimated end date pushed back : Jul 24, 2026 → Aug 28, 2026
Common questions
What is Lenalidomide used for?
A medication used to treat multiple myeloma and certain other blood cancers.
When will Lenalidomide be back in stock in Canada?
The latest manufacturer estimate is Aug 28, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Lenalidomide in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.